Omalizumab

Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI, did not realize she was already on her way to becoming an allergist when working a seemingly ordinary shift in the ED of a rural area in the U.K.

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar Iqbal, MD, therapeutic area lead for respiratory and influenza at Genentech, told Healio here.

SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.

The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.

SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

SAN DIEGO — Patients with three different food allergies who used omalizumab experienced better outcomes than patients who used multi-food oral immunotherapy, driven by lower rates of adverse events, according to an abstract presented here.

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns Hopkins University School of Medicine, told Healio.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.